Get the Stockscreener App
4.06
2.78%
0.11
Kezar Life Sciences Inc stock is traded at $4.06, with a volume of 24,873.
It is up +2.78% in the last 24 hours and down -8.76% over the past month.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
See More
Previous Close:
$3.95
Open:
$3.9
24h Volume:
24,873
Relative Volume:
0.55
Market Cap:
$28.27M
Revenue:
$7.00M
Net Income/Loss:
$-70.79M
P/E Ratio:
-0.419
EPS:
-9.69
Net Cash Flow:
$-64.34M
1W Performance:
+2.27%
1M Performance:
-8.76%
6M Performance:
-32.89%
1Y Performance:
-33.58%
1-Day Range:
$3.90
$4.0831
1-Week Range:
$3.84
$4.0831
52-Week Range:
$3.6201
$9.18
Kezar Life Sciences Inc Stock (KZR) Company Profile
Name
Kezar Life Sciences Inc
Sector
Industry
Phone
650-822-5600
Address
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
4.06 | 28.27M | 7.00M | -70.79M | -64.34M | -9.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-16-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Wells Fargo | Outperform |
| Jul-16-18 | Initiated | William Blair | Outperform |
View All
Kezar Life Sciences Inc Stock (KZR) Latest News
Forecasting Kezar Life Sciences Inc. price range with options dataTrade Analysis Report & Short-Term Trading Opportunity Alerts - Newser
Live market analysis of Kezar Life Sciences Inc.Quarterly Trade Summary & Consistent Profit Trading Strategies - Newser
What does recent volatility data suggest for Kezar Life Sciences Inc.July 2025 Market Mood & Risk Managed Investment Strategies - Newser
Smart tools for monitoring Kezar Life Sciences Inc.’s price actionPortfolio Return Report & Weekly High Conviction Trade Ideas - Newser
Should you wait for a breakout in Kezar Life Sciences Inc.Market Activity Recap & Long-Term Growth Portfolio Plans - Newser
What the charts say about Kezar Life Sciences Inc. todayTrade Risk Summary & Detailed Earnings Play Alerts - Newser
Short interest data insights for Kezar Life Sciences Inc.July 2025 Snapshot & Stock Portfolio Risk Control - Newser
Is this a good reentry point in Kezar Life Sciences Inc.Earnings Trend Report & Weekly Return Optimization Alerts - Newser
What to do if you’re stuck in Kezar Life Sciences Inc.Earnings Overview Report & Real-Time Buy Zone Alerts - Newser
What earnings revisions data tells us about Kezar Life Sciences Inc.Quarterly Risk Review & Weekly Top Gainers Trade List - Newser
Is Kezar Life Sciences Inc. stock entering bullish territoryPortfolio Performance Report & Long-Term Investment Growth Plans - Newser
William Blair Brokers Boost Earnings Estimates for KZR - Defense World
Real time social sentiment graph for Kezar Life Sciences Inc.Quarterly Trade Report & Smart Swing Trading Techniques - Newser
Is Kezar Life Sciences Inc. stock reversal real or fakeQuarterly Portfolio Summary & Smart Allocation Stock Tips - Newser
Technical Bounce Expected in Kezar Life Sciences Inc. Next WeekMarket Performance Report & High Win Rate Trade Alerts - classian.co.kr
Main Inc. stock outlook for YEARJuly 2025 Volume & Comprehensive Market Scan Reports - Newser
What candlestick patterns are forming on Kezar Life Sciences Inc.July 2025 Levels & AI Based Buy and Sell Signals - Newser
How Kezar Life Sciences Inc. stock reacts to Fed policy changesTrade Performance Summary & Safe Swing Trade Setups - Newser
Is Kezar Life Sciences Inc. likely to announce a buybackJuly 2025 Big Picture & Fast Exit and Entry Strategy Plans - thegnnews.com
Kezar Life Sciences Inc. Recovery Likely Here’s What Data ShowsValue Driven Trading Forecast Strategy - beatles.ru
Wells Fargo Keeps Their Hold Rating on Kezar Life Sciences (KZR) - The Globe and Mail
Is it too late to sell Kezar Life Sciences Inc.Trend Reversal & Stepwise Trade Execution Plans - Newser
Should you hold or exit Kezar Life Sciences Inc. nowQuarterly Portfolio Report & Breakout Confirmation Trade Signals - Newser
How to escape a deep drawdown in SoundHound AI Inc. Equity WarrantWeekly Stock Recap & Free Expert Verified Stock Movement Alerts - Newser
Should you hold or exit Sprouts Farmers Market Inc. nowJuly 2025 Spike Watch & Capital Protection Trading Alerts - Newser
Using AI based signals to follow Arrowhead Pharmaceuticals Inc.Weekly Trading Summary & Fast Gaining Stock Reports - Newser
Detecting support and resistance levels for Kezar Life Sciences Inc.July 2025 Big Picture & High Return Stock Watch Alerts - Newser
Can technical indicators confirm Kezar Life Sciences Inc.’s reversalWeekly Earnings Recap & Accurate Intraday Trading Signals - Newser
How to use a screener to detect Kezar Life Sciences Inc. breakoutsJuly 2025 Patterns & Stock Market Timing Techniques - Newser
How Kezar Life Sciences Inc. stock performs during market volatilityMarket Sentiment Summary & Free Weekly Chart Analysis and Trade Guides - Newser
Can Kezar Life Sciences Inc. ride the EV wave2025 Market Overview & High Accuracy Investment Entry Signals - sundaytimes.kr
Kezar Life Sciences' Positive Trial Results and Regulatory Progress Boost Buy Rating - AInvest
Positive Phase 2 Trial Results and Regulatory Progress Bolster Buy Rating for Kezar Life Sciences - TipRanks
Kezar Life Sciences Advances in Autoimmune Hepatitis Trials - TipRanks
Kezar Life Sciences Inc Stock (KZR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kezar Life Sciences Inc Stock (KZR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schiller Mark C. | Chief Operating Officer |
Jul 02 '25 |
Sale |
4.28 |
561 |
2,401 |
2,739 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):